139 filings
8-K
AKLI
Akili Inc
23 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:25pm
ARS
2023 FY
AKLI
Akili Inc
6 Mar 24
Annual report to shareholders
4:28pm
DEFA14A
AKLI
Akili Inc
6 Mar 24
Additional proxy soliciting materials
4:11pm
DEF 14A
AKLI
Akili Inc
Definitive proxy
6 Mar 24
4:07pm
S-8
AKLI
Akili Inc
29 Feb 24
Registration of securities for employees
4:47pm
8-K
3ebbspgnks0xvq0u
29 Feb 24
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
12:00am
8-K
c64n7iw6opsxj3m vs84
26 Feb 24
Japanese Product Now Under Review for Nationwide Marketing Approval
9:04am
PRE 14A
7rndnw wh1
23 Feb 24
Preliminary proxy
7:57am
8-K
bj6613cfsh1za o5hw1
21 Feb 24
Akili Announces Release Date for Fourth Quarter and Full Year 2023
4:11pm
8-K
4hkhorfsf1a2jhp5d
5 Jan 24
Departure of Directors or Certain Officers
4:17pm
8-K
xyptsuv7m0yg
20 Dec 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:58pm
8-K
e7oyaglg
18 Dec 23
EndeavorRx®, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17
8:10am
8-K
y2dldya7l0s4
9 Nov 23
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
oclpee8b250wq0 15q4
27 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:20pm
8-K
29noed8ceppi4erykr
6 Oct 23
Akili Announces Leadership Transition
7:07am
EFFECT
ugca7vvqq i4o
29 Sep 23
Notice of effectiveness
12:00am
POS AM
f2s uutlekn1
27 Sep 23
Prospectus update (post-effective amendment)
7:45am
424B3
8dpuyx4
13 Sep 23
Prospectus supplement
8:11am